- Home
- HRMY vs FRME Comparison
HRMY vs FRME Comparison
Compare HRMY & FRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- FRME
- Stock Information
- Founded
- HRMY 2017
- FRME 1893
- Country
- HRMY United States
- FRME United States
- Employees
- HRMY N/A
- FRME N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- FRME Major Banks
- Sector
- HRMY Health Care
- FRME Finance
- Exchange
- HRMY Nasdaq
- FRME Nasdaq
- Market Cap
- HRMY 2.1B
- FRME 2.3B
- IPO Year
- HRMY 2020
- FRME N/A
- Fundamental
- Price
- HRMY $32.29
- FRME $39.45
- Analyst Decision
- HRMY Strong Buy
- FRME Buy
- Analyst Count
- HRMY 9
- FRME 3
- Target Price
- HRMY $55.33
- FRME $46.67
- AVG Volume (30 Days)
- HRMY 678.1K
- FRME 199.6K
- Earning Date
- HRMY 10-28-2025
- FRME 10-23-2025
- Dividend Yield
- HRMY N/A
- FRME 3.63%
- EPS Growth
- HRMY 58.41
- FRME 23.41
- EPS
- HRMY 3.10
- FRME 3.85
- Revenue
- HRMY $772,527,000.00
- FRME $638,723,000.00
- Revenue This Year
- HRMY $20.09
- FRME $14.28
- Revenue Next Year
- HRMY $16.86
- FRME $4.02
- P/E Ratio
- HRMY $10.42
- FRME $10.29
- Revenue Growth
- HRMY 17.74
- FRME 6.22
- 52 Week Low
- HRMY $26.47
- FRME $33.13
- 52 Week High
- HRMY $41.61
- FRME $46.13
- Technical
- Relative Strength Index (RSI)
- HRMY 30.41
- FRME 42.99
- Support Level
- HRMY $31.61
- FRME $39.93
- Resistance Level
- HRMY $37.05
- FRME $40.48
- Average True Range (ATR)
- HRMY 1.18
- FRME 0.77
- MACD
- HRMY -0.59
- FRME -0.25
- Stochastic Oscillator
- HRMY 10.19
- FRME 16.77
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.